Polyomavirus-associated nephropathy in renal transplantation

Interdisciplinary analyses and recommendations

Hans H. Hirsch, Daniel C. Brennan, Cinthia B. Drachenberg, Fabrizio Ginevri, Jennifer Gordon, Ajit P. Limaye, Michael J. Mihatsch, Volker Nickeleit, Emilia Ramos, Parmjeet Randhawa, Ron Shapiro, Juerg Steiger, Manikkam Suthanthiran, Jennifer Trofe

Research output: Contribution to journalReview article

693 Citations (Scopus)

Abstract

Polyomavirus-associated nephropathy (PVAN) is an emerging cause of kidney transplant failure affecting 1-10% of patients. As uncertainty exists regarding risk factors, diagnosis, and intervention, an independent panel of experts reviewed the currently available evidence and prepared this report. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense immunosuppression. No specific immunosuppressive drug is exclusively associated with PVAN, but most cases reported to date arise while the patient is on triple immunosuppressive combinations, often comprising tacrolimus and/or mycophenolate mofetil plus corticosteroids. Immunologic control of polyomavirus replication can be achieved by reducing, switching, and/or discontinuing components of the immunosuppressive regimen, but the individual's risk of rejection should be considered. The success rate of this intervention is increased with earlier diagnosis. Therefore, it is recommended that all renal transplant recipients should be screened for BKV replication in the urine: 1) every three months during the first two years posttransplant; 2) when allograft dysfunction is noted; and 3) when allograft biopsy is performed. A positive screening result should be confirmed in <4 weeks and assessed by quantitative assays (e.g. BKV DNA or RNA load in plasma or urine). Definitive diagnosis of PVAN requires allograft biopsy. If PVAN and concurrent acute rejection is diagnosed, antirejection treatment should be considered, coupled with subsequently reducing immunosuppression. The antiviral cidofovir is not approved for PVAN, but investigational use at low doses (0.25-0.33 mg/kg intravenously biweekly) without probenicid should be considered for refractory cases. Retransplantation after renal allograft loss to PVAN remains a treatment option for patients clearing polyomavirus replication.

Original languageEnglish
Pages (from-to)1277-1286
Number of pages10
JournalTransplantation
Volume79
Issue number10
DOIs
Publication statusPublished - 27 May 2005
Externally publishedYes

Fingerprint

Polyomavirus
Kidney Transplantation
BK Virus
Allografts
Immunosuppressive Agents
Immunosuppression
Urine
Mycophenolic Acid
Kidney
Biopsy
Tacrolimus
Virus Replication
Uncertainty
Renal Insufficiency
Antiviral Agents
Early Diagnosis
Adrenal Cortex Hormones
RNA
Transplants

Keywords

  • Allograft
  • BK virus
  • BKV polyomavirus
  • Cyclosporine
  • Kidney
  • Mycophenolate mofetil
  • Nephropathy
  • Sirolimus
  • Steroids
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Hirsch, H. H., Brennan, D. C., Drachenberg, C. B., Ginevri, F., Gordon, J., Limaye, A. P., ... Trofe, J. (2005). Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation, 79(10), 1277-1286. https://doi.org/10.1097/01.TP.0000156165.83160.09

Polyomavirus-associated nephropathy in renal transplantation : Interdisciplinary analyses and recommendations. / Hirsch, Hans H.; Brennan, Daniel C.; Drachenberg, Cinthia B.; Ginevri, Fabrizio; Gordon, Jennifer; Limaye, Ajit P.; Mihatsch, Michael J.; Nickeleit, Volker; Ramos, Emilia; Randhawa, Parmjeet; Shapiro, Ron; Steiger, Juerg; Suthanthiran, Manikkam; Trofe, Jennifer.

In: Transplantation, Vol. 79, No. 10, 27.05.2005, p. 1277-1286.

Research output: Contribution to journalReview article

Hirsch, HH, Brennan, DC, Drachenberg, CB, Ginevri, F, Gordon, J, Limaye, AP, Mihatsch, MJ, Nickeleit, V, Ramos, E, Randhawa, P, Shapiro, R, Steiger, J, Suthanthiran, M & Trofe, J 2005, 'Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations', Transplantation, vol. 79, no. 10, pp. 1277-1286. https://doi.org/10.1097/01.TP.0000156165.83160.09
Hirsch, Hans H. ; Brennan, Daniel C. ; Drachenberg, Cinthia B. ; Ginevri, Fabrizio ; Gordon, Jennifer ; Limaye, Ajit P. ; Mihatsch, Michael J. ; Nickeleit, Volker ; Ramos, Emilia ; Randhawa, Parmjeet ; Shapiro, Ron ; Steiger, Juerg ; Suthanthiran, Manikkam ; Trofe, Jennifer. / Polyomavirus-associated nephropathy in renal transplantation : Interdisciplinary analyses and recommendations. In: Transplantation. 2005 ; Vol. 79, No. 10. pp. 1277-1286.
@article{9c29501c55e44e7db25958b2e9c498da,
title = "Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations",
abstract = "Polyomavirus-associated nephropathy (PVAN) is an emerging cause of kidney transplant failure affecting 1-10{\%} of patients. As uncertainty exists regarding risk factors, diagnosis, and intervention, an independent panel of experts reviewed the currently available evidence and prepared this report. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense immunosuppression. No specific immunosuppressive drug is exclusively associated with PVAN, but most cases reported to date arise while the patient is on triple immunosuppressive combinations, often comprising tacrolimus and/or mycophenolate mofetil plus corticosteroids. Immunologic control of polyomavirus replication can be achieved by reducing, switching, and/or discontinuing components of the immunosuppressive regimen, but the individual's risk of rejection should be considered. The success rate of this intervention is increased with earlier diagnosis. Therefore, it is recommended that all renal transplant recipients should be screened for BKV replication in the urine: 1) every three months during the first two years posttransplant; 2) when allograft dysfunction is noted; and 3) when allograft biopsy is performed. A positive screening result should be confirmed in <4 weeks and assessed by quantitative assays (e.g. BKV DNA or RNA load in plasma or urine). Definitive diagnosis of PVAN requires allograft biopsy. If PVAN and concurrent acute rejection is diagnosed, antirejection treatment should be considered, coupled with subsequently reducing immunosuppression. The antiviral cidofovir is not approved for PVAN, but investigational use at low doses (0.25-0.33 mg/kg intravenously biweekly) without probenicid should be considered for refractory cases. Retransplantation after renal allograft loss to PVAN remains a treatment option for patients clearing polyomavirus replication.",
keywords = "Allograft, BK virus, BKV polyomavirus, Cyclosporine, Kidney, Mycophenolate mofetil, Nephropathy, Sirolimus, Steroids, Tacrolimus",
author = "Hirsch, {Hans H.} and Brennan, {Daniel C.} and Drachenberg, {Cinthia B.} and Fabrizio Ginevri and Jennifer Gordon and Limaye, {Ajit P.} and Mihatsch, {Michael J.} and Volker Nickeleit and Emilia Ramos and Parmjeet Randhawa and Ron Shapiro and Juerg Steiger and Manikkam Suthanthiran and Jennifer Trofe",
year = "2005",
month = "5",
day = "27",
doi = "10.1097/01.TP.0000156165.83160.09",
language = "English",
volume = "79",
pages = "1277--1286",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Polyomavirus-associated nephropathy in renal transplantation

T2 - Interdisciplinary analyses and recommendations

AU - Hirsch, Hans H.

AU - Brennan, Daniel C.

AU - Drachenberg, Cinthia B.

AU - Ginevri, Fabrizio

AU - Gordon, Jennifer

AU - Limaye, Ajit P.

AU - Mihatsch, Michael J.

AU - Nickeleit, Volker

AU - Ramos, Emilia

AU - Randhawa, Parmjeet

AU - Shapiro, Ron

AU - Steiger, Juerg

AU - Suthanthiran, Manikkam

AU - Trofe, Jennifer

PY - 2005/5/27

Y1 - 2005/5/27

N2 - Polyomavirus-associated nephropathy (PVAN) is an emerging cause of kidney transplant failure affecting 1-10% of patients. As uncertainty exists regarding risk factors, diagnosis, and intervention, an independent panel of experts reviewed the currently available evidence and prepared this report. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense immunosuppression. No specific immunosuppressive drug is exclusively associated with PVAN, but most cases reported to date arise while the patient is on triple immunosuppressive combinations, often comprising tacrolimus and/or mycophenolate mofetil plus corticosteroids. Immunologic control of polyomavirus replication can be achieved by reducing, switching, and/or discontinuing components of the immunosuppressive regimen, but the individual's risk of rejection should be considered. The success rate of this intervention is increased with earlier diagnosis. Therefore, it is recommended that all renal transplant recipients should be screened for BKV replication in the urine: 1) every three months during the first two years posttransplant; 2) when allograft dysfunction is noted; and 3) when allograft biopsy is performed. A positive screening result should be confirmed in <4 weeks and assessed by quantitative assays (e.g. BKV DNA or RNA load in plasma or urine). Definitive diagnosis of PVAN requires allograft biopsy. If PVAN and concurrent acute rejection is diagnosed, antirejection treatment should be considered, coupled with subsequently reducing immunosuppression. The antiviral cidofovir is not approved for PVAN, but investigational use at low doses (0.25-0.33 mg/kg intravenously biweekly) without probenicid should be considered for refractory cases. Retransplantation after renal allograft loss to PVAN remains a treatment option for patients clearing polyomavirus replication.

AB - Polyomavirus-associated nephropathy (PVAN) is an emerging cause of kidney transplant failure affecting 1-10% of patients. As uncertainty exists regarding risk factors, diagnosis, and intervention, an independent panel of experts reviewed the currently available evidence and prepared this report. Most cases of PVAN are elicited by BK virus (BKV) in the context of intense immunosuppression. No specific immunosuppressive drug is exclusively associated with PVAN, but most cases reported to date arise while the patient is on triple immunosuppressive combinations, often comprising tacrolimus and/or mycophenolate mofetil plus corticosteroids. Immunologic control of polyomavirus replication can be achieved by reducing, switching, and/or discontinuing components of the immunosuppressive regimen, but the individual's risk of rejection should be considered. The success rate of this intervention is increased with earlier diagnosis. Therefore, it is recommended that all renal transplant recipients should be screened for BKV replication in the urine: 1) every three months during the first two years posttransplant; 2) when allograft dysfunction is noted; and 3) when allograft biopsy is performed. A positive screening result should be confirmed in <4 weeks and assessed by quantitative assays (e.g. BKV DNA or RNA load in plasma or urine). Definitive diagnosis of PVAN requires allograft biopsy. If PVAN and concurrent acute rejection is diagnosed, antirejection treatment should be considered, coupled with subsequently reducing immunosuppression. The antiviral cidofovir is not approved for PVAN, but investigational use at low doses (0.25-0.33 mg/kg intravenously biweekly) without probenicid should be considered for refractory cases. Retransplantation after renal allograft loss to PVAN remains a treatment option for patients clearing polyomavirus replication.

KW - Allograft

KW - BK virus

KW - BKV polyomavirus

KW - Cyclosporine

KW - Kidney

KW - Mycophenolate mofetil

KW - Nephropathy

KW - Sirolimus

KW - Steroids

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=21144443075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144443075&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000156165.83160.09

DO - 10.1097/01.TP.0000156165.83160.09

M3 - Review article

VL - 79

SP - 1277

EP - 1286

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -